|
Market Closed -
London S.E.
18:35:05 16/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 12,446.00 GBX | -1.98% |
|
+4.66% | -9.75% |
| 10-16 | FTSE forges ahead but banks stutter on tax threat | AN |
| 10-16 | UK government courted UBS over potential London move - FT | AN |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 257,525 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -10.52% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 277,630 | 269,984 | 261,875 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -10.78% | -2.75% | -3% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 21.7x | 18.6x | 16.7x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.76x | 4.13x | 3.55x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.3x | 1.1x | 1.4x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.06x | 3.82x | 3.61x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.38x | 4.01x | 3.67x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.6x | 11.1x | 9.78x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 13.2x | 11.6x | 10.3x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28x | 21x | 17.8x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.57% | 4.77% | 5.6% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.342 | 3.547 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.01% | 2.14% | 2.2% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.65 | 8.904 | 9.969 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.7% | 39.8% | 36.7% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,403 | 67,370 | 71,401 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,115 | 24,327 | 26,764 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,069 | 23,252 | 25,511 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,792 | 13,652 | 15,178 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 20,105 | 12,460 | 4,350 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 166.04 | 166.04 | 166.04 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 A | 2/9/23 A | 2/8/24 A | 2/6/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22x | 4.43x | 12.71x | 1.99% | 261B | |
| 35.8x | 12.9x | 27.02x | 0.55% | 1,116B | |
| 37.07x | 6.25x | 17.38x | 2.11% | 610B | |
| 36.17x | 8.31x | 17.13x | 2.45% | 501B | |
| 112.15x | 5.92x | 25.35x | 2.35% | 358B | |
| 20.49x | 5x | 12.4x | 2.64% | 366B | |
| 21.24x | 5.55x | 13.66x | 2.88% | 288B | |
| 27.56x | 7.08x | 12.68x | 2.32% | 235B | |
| -45.98x | 7.04x | 27.26x | 2.1% | 195B | |
| 11.6x | 4.27x | 8.72x | 4.33% | 175B | |
| Average | 27.81x | 6.67x | 17.43x | 2.37% | 410.44B | |
| Weighted average by Cap. | 34.05x | 8.00x | 19.50x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
